Evidence map›Paper›PMID 39662065›Full record

GuidelineHormone research in paediatrics2024

ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.

Michael J Haller, Kirstine J Bell, Rachel E J Besser, Kristina Casteels, Jenny J Couper, Maria E Craig, Helena Elding Larsson, Laura Jacobsen, Karin Lange, Tal Oron and 7 more

Registry-linked trialAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Hormone research in paediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07492550 (T1D WATCH Study, a Comprehensive Screening for Type 1 Diabetes Autoantibodies in Children), which is not on this map. Cited by 68 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07492550 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

T1D WATCH Study, a Comprehensive Screening for Type 1 Diabetes Autoantibodies in Children: A Proactive Approach to Early Detection and Intervention

Typeobservational_patient_registrySponsorFabiana Sherine Ganem dos SantosRan2026 to 2027Enrolled2,200ConditionsDiabete Type 1
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Michael J HallerDivision of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
Kirstine J BellCharles Perkins Centre and Faculty Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Rachel E J BesserCentre for Human Genetics, NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.
Kristina CasteelsDepartment of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
Jenny J CouperWomen's and Children's Hospital, North Adelaide, South Australia, Australia.
Maria E CraigThe Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Helena Elding LarssonDepartment of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Laura JacobsenDivision of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
Karin LangeDepartment of Medical Psychology, Hannover Medical School, Hannover, Germany.
Tal OronThe Institute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel.
Emily K SimsDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Cate SpeakeCenter for Interventional Immunology, Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA.
Mustafa TosurThe Division of Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
Francesca UliviFondazione Italiana Diabete ETS, Milan, Italy.
Anette-G ZieglerInstitute of Diabetes Research, Helmholtz Zentrum München, and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Diane K WherrettDivision of Endocrinology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
M Loredana MarcovecchioDepartment of Paediatrics, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Funding

Project 3P01AI042288 · NIAID · UNIVERSITY OF FLORIDA · PI Todd Michael Brusko · 1997 to 2026
$32.9M
NIAID NIH HHS P01 AI042288
6 · The paper itself

Abstract

The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed. The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. In addition, a review of clinical trials designed to delay progression to Stage 3 T1D and efforts seeking to preserve beta-cell function in those with Stage 3 T1D are included. Lastly, opportunities and challenges associated with the recent US Food and Drug Administration (FDA) approval of teplizumab as an immunotherapy to delay progression are discussed.

Indexed as

Diabetes Mellitus, Type 1Insulin-Secreting CellsAdolescentAntibodies, Monoclonal, HumanizedChildConsensusHumansMaleAntibodies, Monoclonal, HumanizedBeta cellChildrenPreservationScreeningStagesType 1 diabetes

Identifiers

PMID39662065
PMCPMC11854978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.